

SPECIAL ARTICLE

The Value of Medical Spending in the United States, 1960–2000

David M. Cutler, Ph.D., Allison B. Rosen, M.D., M.P.H., Sc.D.,
and Sandeep Vijan, M.D.

ABSTRACT

From the Department of Economics, Harvard University, and the National Bureau of Economic Research — both in Cambridge, Mass. (D.M.C.); and the Center for Practice Management and Outcomes Research, Ann Arbor Veterans Affairs Medical Center, and the Division of General Medicine, University of Michigan Health System — both in Ann Arbor (A.B.R., S.V.). Address reprint requests to Dr. Cutler at the Department of Economics, Harvard University, 1875 Cambridge St., Cambridge, MA 02138, or at dcutler@harvard.edu.

N Engl J Med 2006;355:920-7.
Copyright © 2006 Massachusetts Medical Society.

BACKGROUND

The increased use of medical therapies has led to increased medical costs. To provide insight into the value of this increased spending, we compared gains in life expectancy with the increased costs of care from 1960 through 2000.

METHODS

We estimated life expectancy in 1960, 1970, 1980, 1990, and 2000 for four age groups. To control for the influence of nonmedical factors on survival, we assumed in our base-case analysis that 50 percent of the gains were due to medical care. We compared the adjusted increases in life expectancy with the lifetime cost of medical care in the same years.

RESULTS

From 1960 through 2000, the life expectancy for newborns increased by 6.97 years, lifetime medical spending adjusted for inflation increased by approximately \$69,000, and the cost per year of life gained was \$19,900. The cost increased from \$7,400 per year of life gained in the 1970s to \$36,300 in the 1990s. The average cost per year of life gained in 1960–2000 was approximately \$31,600 at 15 years of age, \$53,700 at 45 years of age, and \$84,700 at 65 years of age. At 65 years of age, costs rose more rapidly than did life expectancy: the cost per year of life gained was \$121,000 between 1980 and 1990 and \$145,000 between 1990 and 2000.

CONCLUSIONS

On average, the increases in medical spending since 1960 have provided reasonable value. However, the spending increases in medical care for the elderly since 1980 are associated with a high cost per year of life gained. The national focus on the rise in medical spending should be balanced by attention to the health benefits of this increased spending.

ADVANCES IN MEDICAL CARE HAVE LED to sustained increases in medical spending over time. Adjusted for inflation, annual medical spending per person has increased from approximately \$700 in 1960 to more than \$6,000 today, tripling as a share of the gross domestic product (GDP).¹ At least half this increase is a result of more care, not higher prices for existing care.²

An evaluation of whether increased medical spending is useful requires the valuation of the increase in care. The enormous growth in spending has led many to argue that the increasing costs are excessive.³ Others, however, suggest that spending more may provide good value, whether measured in costs per year of life gained or in overall measures of economic benefit.⁴⁻⁷ The vast literature on the cost-effectiveness of specific medical treatments and other interventions suggests that many (though certainly not all) medical treatments provide reasonable value.⁸ However, there has been comparatively little effort to understand the value of the medical system as a whole: Is the increase in spending by more than a factor of eight worth it?

We addressed this question by examining how medical spending has translated into gains in survival. We measured the increase in medical spending from 1960 through 2000 and compared it with the number of additional years of life lived, focusing on the gains in life expectancy that were likely to be due to medical care. We assumed in our base case that 50 percent of improvements in longevity resulted from medical care. We also conducted sensitivity analyses using various assumptions about the proportion of life-expectancy gains that was attributable to health care.

METHODS

We estimated life expectancies and the projected medical spending for four age groups in 1960, 1970, 1980, 1990, and 2000, according to the mortality rates and costs that prevailed in each year. For example, when calculating the lifetime costs (i.e., costs from birth) of health care for a newborn in 1960, we used the 1960 values for spending in all ages. In this way, we obtained an accurate picture of the medical system as it existed at each time, and we were able to explore how that picture changed over time.

LIFE EXPECTANCY

Our data on life expectancy were based on U.S. life tables for 1959–1961, 1969–1971, 1979–1981, 1989–1991, and 2000.⁹ For simplicity, we refer to the three-year periods by the middle year (1960, 1970, 1980, 1990). To estimate changes in life expectancy according to cause, we used cause-deletion methods.¹⁰ Specifically, we obtained the rates of death from each cause in 1960 according to age. We then added the age-specific change in the mortality rate between 1960 and 2000 for a particular cause to the age-specific overall mortality rate in 1960 and calculated the life expectancy according to the new mortality rate. The difference between the life expectancy calculated with the new mortality rate and the life expectancy in 1960 was considered to reflect the effect of that cause on life expectancy.

We assumed that a portion of the gains in life expectancy were related to medical care. Analyses aggregated from treatments clearly shown to be medically effective suggest that at least half the life-expectancy gains since 1950 are due to medical advances.¹¹⁻¹³ About 90 percent of the gains in life expectancy are attributable to improvements in the rates of death in infancy and the rates of death from cardiovascular disease. Prevailing estimates suggest that at least half the reduction in these rates are due to medical care.^{4,14-23} We therefore assumed in our base case that 50 percent of the total gains in life expectancy were due to medical care.

We examined this assumption by considering the importance of two causes of death that are unlikely to be due to changing medical treatment. The first was death attributable to smoking. Rates of smoking among adults fell from 42 percent in 1960 to 22 percent in 2000. To estimate the changes in life expectancy that were attributable to reduced rates of smoking, we constructed an alternative time series for mortality in 1970, 1980, 1990, and 2000, assuming that smoking rates were fixed at 1960 levels — in essence, assuming that none of the decline in the rate of smoking was due to medical treatment. Data on the prevalence of smoking were from the National Health Interview surveys for 1965–2000²⁴ and from a survey of adolescents in California.²⁵ Because the surveys did not collect information on smoking until 1965, the ratio of per capita cigarette use in 1960 was compared with that for 1965 to extrapo-

duced rate of death from cardiovascular disease. An additional 1.35 years (19 percent) resulted from a reduced rate of death in infancy. A reduced rate of death from external causes led to an additional increase of 0.36 year (5 percent). The reduction in the rate of death from smoking (included in the rate of death from cardiovascular disease and other causes) led to an increase in life expectancy of 1.1 years (16 percent) (data not shown). The combined effect of reduced rates of death from external causes and smoking, 21 percent, is less than the increase in longevity of 50 percent that we attributed to nonmedical factors.

Estimates of the present value of medical spending for each of the four age groups, calculated with the use of age-specific spending rates that prevailed in each year, are listed in Table 3. In 1960, lifetime spending from birth was about \$14,000 per person. That amount had increased to more than \$83,000 by 2000, an increase by a factor of nearly six. At older ages, medical spending increased even more between 1960 and 2000 — by a factor of more than 13 for people 65 years of age or older, for example.

The lifetime incremental costs per year of life gained, based on the assumption that 50 percent of such increases were due to medical care, are shown in Figure 1. From birth, during the entire period from 1960 through 2000, an average of \$19,900 was spent per year of life gained. Costs per year of life gained were lower in the first two decades than in the third and fourth decades but costs per year of life for newborns never exceeded \$40,000 per year. At older ages, there were substantial increases in the cost of each additional year of life gained. For example, the average cost per year of life gained at 65 years of age was about \$84,700 during the entire 1960–2000 period but rose from \$75,100 between 1960 and 1970 to \$145,000 between 1990 and 2000.

We used sensitivity analyses to examine how varying the proportion of increases in life expectancy gains assumed to be due to medical care would affect the estimates of cost-effectiveness (Fig. 2). If 25 percent of the gains in life expectancy were due to health care, then the average cost per year of life gained between 1960 and 2000 would have ranged from \$39,800 at birth to \$169,400 at 65 years of age. According to this scenario, each one-year increase in life expectancy cost more than \$70,000 between 1990 and 2000 for each age group. Conversely, if 75 percent of the

Table 2. Causes of Increases in Life Expectancy among Newborns, 1960–2000.*

Cause	Increase in Life Expectancy	Relative Contribution
	yr	%
Reduction in rate of death from cardiovascular disease	4.88	70
Reduction in rate of death in infancy	1.35	19
Reduction in rate of death from external causes	0.36	5
Reduction in rate of death from pneumonia or influenza	0.28	4
Reduction in rate of death from cancer	0.19	3
Total	6.97	100

* The data do not sum to the total because of slight increases in the rates of death from other causes (not listed) and because of rounding.

increase in life expectancy were due to health care, then the average cost per year of life gained between 1960 and 2000 would have ranged from \$13,300 for newborns to \$56,500 for people 65 years of age or older.

DISCUSSION

Medical spending has increased at more than 10 percent per year for most of the past four decades, largely as a result of the development and widespread use of new medical techniques.² This dramatic increase in spending has contributed to political pressure to restrain costs.³ Yet one of the most important questions remains unanswered: What is the value of this medical spending? We attempted to answer that question by comparing the trends in spending with the trends in life expectancy. During the period from 1960 through 2000, we estimated that increased spending on health care at birth resulted in an average cost of \$19,900 per year of life gained. In analyses including spending and the increase in life expectancy for people 65 years of age, the average cost per additional year of life was about \$84,700.

The value of a year of life as used in medical decision-making (known as the value of a statistical life) is the subject of some debate. Viscusi and Aldy²⁹ estimated the value of a statistical life for people of working age at approximately \$7 million. For a person who is roughly 45 years old and thus has a remaining life expectancy of 30 years, the value is more than \$200,000 per year of life re-

Table 3. Present Value of Average Medical Spending per Person According to Age Group and Year.*

Age	Average per Capita Spending					Cumulative Change (1960–2000)
	1960	1970	1980	1990	2000	
	\$					
Newborn	13,943	25,528	37,085	56,120	83,307	69,364
15 Yr	18,700	32,704	47,155	69,457	102,490	83,790
45 Yr	17,141	35,266	63,275	100,983	148,014	130,873
65 Yr	11,495	34,526	69,819	116,097	158,549	147,054

* Values are expressed in 2002 U.S. dollars. Costs were discounted with the use of an interest rate of 3 percent. Because of this discounting and the fact that not everyone lives to an advanced age, the present value of lifetime spending at younger ages need not exceed the present value of spending at older ages.

maintaining.⁷ Some studies recommend a value of \$100,000 per year of life,^{4,30} whereas the National Institute for Health and Clinical Excellence, whose analysis is used to inform decisions about health coverage by the British National Health Service, seems to use a value of £25,000 to £35,000 per year of life (roughly \$50,000) as a general upper limit, though this is not specifically stated as policy.³¹

According to virtually any commonly cited value of a year of life, we found that if medical care accounts for about half the gains in life expectancy, then the increased spending has, on average, been worth it. However, the current trends are a cause for concern. There has been a sharp increase in the cost per additional year of life

gained during the past two decades, primarily among the elderly. Analyses focused on spending and on the increase in life expectancy beginning at 65 years of age showed that the incremental cost of an additional year of life rose from \$46,800 in the 1970s to \$145,000 in the 1990s. The former amount certainly reflects a good value, but the latter fails to meet many cost–benefit criteria. Furthermore, it appears that although the rate of increase in spending had stabilized, if not declined, by 2000 for the newborn and 15-year-old groups, this rate is substantially outpacing the rate of increase in life expectancy in older age groups. If this trend continues in the elderly, the cost-effectiveness of medical care will continue to decrease at older ages.

The reasons for the substantially increased cost per year of life gained in older age groups cannot be ascertained from our analyses, although other investigators have examined possible reasons.³ One is that the “low-hanging fruit” (less expensive therapies such as antihypertensive medications) were picked first, and incremental advances thereafter have necessarily been more costly. Another is that relatively more care for elderly patients than for younger patients is palliative or residential, which results in increased spending for the elderly and does improve quality of life but may not improve longevity.

Clearly, not all improvements in the mortality rate resulted from medical spending, but we used a conservative method to estimate the percentage that did. Consistently with past analyses,^{11–13} we assumed that only 50 percent of the reduction in the mortality rate was due to medical care. This assumption is likely to be reasonable, given our





Figure 1. Longitudinal Trends in the Costs per Year of Life Gained in Four Age Groups.

Spending per year of life gained was defined by the change in spending over the decade divided by the change in expected years of life over the decade.



finding that 90 percent of the increases in life expectancy during the past four decades have resulted from reductions in the rate of death from cardiovascular disease and death in infancy. Although reductions in the rate of death from cardiovascular causes are multifactorial, prior research has suggested that at least half the reductions in the rate have resulted from medical advances.¹⁴⁻¹⁷ Among infants, more than half the reduction in the mortality rate between 1960 and 2000 resulted from a reduced rate of neonatal death among low-birth-weight infants (weighing <2500 g), which is due almost entirely to medical advances.^{18,19,21-23}

To validate our assumption, we considered other factors that were unlikely to be the result of medical care. Reduced rates of death from external causes and death related to smoking together accounted for 21 percent of the increase in longevity, well below the 50 percent that we attributed to nonmedical factors. Even if only 25 percent of the gains in longevity were due to medical care, the value of medical care is reasonable, on average.

Our primary conclusion is that although medical spending has increased over time, the return on spending has been high. In considering health

policy, the concern about high medical costs needs to be balanced by the benefits of the care received.

Our results contrast with the conclusions that are often drawn from international data. The United States spends more on health care than other countries do, with similar or poorer overall outcomes. Of course, differences in culture, lifestyle, and social systems may confound these international comparisons. Still, it is clear that the U.S. health care system is not as efficient as it could be,³² and improving its efficiency is an important goal. However, our results suggest that the increase in spending is not solely attributable to an increase in inefficiency. Indeed, medical spending has increased at roughly the same rate in all countries.^{2,33} Taken as a whole, the average return on the increased spending has been high.

One possible scenario for the future of health care is that the costs per year of life gained will continually increase, resulting in wasted resources. However, extrapolation of any kind is inherently uncertain, and particularly so for medical advances. The genetic revolution is opening new avenues for medical inquiry, and some very cost-effective therapies could emerge. In addition,

quality-improvement initiatives could increase the value of every dollar spent.

A number of limitations of our study should be mentioned. First, our estimate that 50 percent of the increase in longevity results from medical care is uncertain. Although reduced rates of death from tobacco use and from external causes accounted for only 21 percent of the increase in life expectancy, we did not consider all causes of changes in life expectancy that were due to non-medical interventions. The most obvious omissions were the increased rate of obesity and the spread of acquired immunodeficiency syndrome, each of which results in worsened health. Second, our analysis was based on mortality alone, not on changes in the quality of life. Consistent data on the quality of life were not available for the period from 1960 through 2000. However, studies suggest that there were substantial improvements in the quality of life during this period, especially among the elderly.^{13,34} Thus, our estimates are likely to have understated the value of medical spending. Finally, although we excluded gains in life expectancy that were due to nonmedical interventions, we did not exclude their associated costs,

owing to the difficulty of disaggregating them from the overall costs of health care. This resulted in the overstatement of cost increases and thus the understatement of the value of medical advances.

In conclusion, although medical spending has increased substantially during the past 40 years, the money spent has provided good value. However, temporal trends suggest that the value of health care spending is decreasing over time, particularly for older age groups. We need to continue tracking trends in health care spending and its benefits to ensure that resources are allocated wisely. Such efforts should focus on specific diseases in order to provide a more detailed picture of the value of health care both within disease categories and across a spectrum of common diseases over time. Also, the United States should modify its system of tracking the health sector to include a measure of population health in addition to spending, so that policymakers and the public have an informed picture of the benefits obtained for the money spent.

Supported by grants from the National Institute on Aging (R01 AG015911) and the Lasker Foundation.

No potential conflict of interest relevant to this article was reported.

REFERENCES

- National health expenditure accounts. Baltimore: Centers for Medicare and Medicaid Services, 2005. (Accessed August 4, 2006, at <http://www.cms.hhs.gov/statistics/nhe/default.asp>.)
- Newhouse JP. Medical care costs: how much welfare loss? *J Econ Perspect* 1992; 6:3-29.
- Bodenheimer T. High and rising health care costs. Part 1: seeking an explanation. *Ann Intern Med* 2005;142:847-54.
- Cutler DM. Your money or your life: strong medicine for America's health care system. Oxford, England: Oxford University Press, 2004.
- Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. *Health Aff (Millwood)* 2001;20(5):241-51.
- Nordhaus W. The health of nations: the contribution of improved health to living standards. In: Murphy KM, Topel RH, eds. *Measuring the gains from medical research: an economic approach*. Chicago: University of Chicago Press, 2003:9-40.
- Murphy KM, Topel RH. The economic value of medical research. In: Murphy KM, Topel RH, eds. *Measuring the gains from medical research: an economic approach*. Chicago: University of Chicago Press, 2003:41-73.
- Comprehensive table of cost-utility ratios, 1976-2000. Boston: Harvard School of Public Health, 2003. (Accessed August 4, 2006, at http://www.hsph.harvard.edu/cearegistry/data/1976-2001_CEratio_comprehensive_4-7-2004.pdf.)
- National Vital Statistics Reports. United States life tables. Atlanta: Centers for Disease Control and Prevention, 2005. (Accessed August 4, 2006, at <http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/lftbls.htm>.)
- Tsai SP, Lee ES, Hardy RJ. The effect of a reduction in leading causes of death: potential gains in life expectancy. *Am J Public Health* 1978;68:966-71.
- Bunker JP. The role of medical care in contributing to health improvements within societies. *Int J Epidemiol* 2001;30: 1260-3.
- Bunker JP, Frazier HS, Mosteller F. Improving health: measuring effects of medical care. *Millbank Q* 1994;72:225-58.
- Bunker JP. Medicine matters after all. *J R Coll Physicians Lond* 1995;29:105-12.
- Goldman L, Cook EF. The decline in ischemic heart disease mortality rates: an analysis of the comparative effects of medical interventions and changes in lifestyle. *Ann Intern Med* 1984;101:825-36.
- Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. *Heart* 1999;81:380-6.
- Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. *JAMA* 1997;277:535-42.
- Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. *BMJ* 2005;331:614.
- Williams RL, Chen PM. Identifying the sources of the recent decline in perinatal mortality rates in California. *N Engl J Med* 1982;306:207-14.
- Richardson DK, Gray JE, Gortmaker SL, Goldmann DA, Pursley DM, McCormick MC. Declining severity adjusted mortality: evidence of improving neonatal intensive care. *Pediatrics* 1998;102:893-9.
- Li G, Shahpar C, Grabowski JG, Baker SP. Secular trends of motor vehicle mortality in the United States, 1910-1994. *Accid Anal Prev* 2001;33:423-32.
- Kliegman RM. Neonatal technology, perinatal survival, social consequences, and the perinatal paradox. *Am J Public Health* 1995;85:909-13.

22. Cutler DM, Meara ER. The technology of birth: is it worth it? In: Garber AM, ed. *Frontiers in health policy research*. Cambridge, Mass.: MIT Press, 2000:33-67.
23. Lee KS, Paneth N, Gartner LM, Pearlman MA, Gruss L. Neonatal mortality: an analysis of the recent improvement in the United States. *Am J Public Health* 1980; 70:15-21.
24. Tobacco Information and Prevention Source (TIPS). National Health Interview surveys, selected years — United States, 1965-2000. Atlanta: Centers for Disease Control and Prevention, 2005. (Accessed August 4, 2006, at http://www.cdc.gov/tobacco/research_data/adults_prev/adstat1print.htm.)
25. Anderson CM, Burns DM. Patterns of adolescent initiation rates over time: national and California data. In: *Smoking and tobacco control*. Monograph no. 14: changing adolescent smoking prevalence. Washington, D.C.: National Cancer Institute, 2001.
26. Giovino GA, Schooley MW, Zhu BP, et al. Surveillance for selected tobacco-use behaviors — United States, 1900–1994. *MMWR CDC Surveill Summ* 1994;43:1-43.
27. Thun MJ, Myers DG, Day-Lally C, et al. Age and the exposure-response relationships between cigarette smoking and premature death in Cancer Prevention Study II. In: *Smoking and tobacco control*. Monograph no. 8: changes in cigarette-related disease risks and their implications for prevention and control. Washington, D.C.: National Cancer Institute, 1997.
28. Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. *Health Aff (Millwood)* 2004;23(4):176-83.
29. Viscusi WK, Aldy J. The value of a statistical life: a critical review of market estimates throughout the world. *J Risk Uncertainty* 2003;27:5-76.
30. Tolley GS, Kenkel DS, Fabian RG. Valuing health for policy: an economic approach. Chicago: University of Chicago Press, 1994.
31. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. *BMJ* 2004;329:224-7.
32. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. *Ann Intern Med* 2003;138:288-98.
33. Anderson GF, Frogner BK, Johns RA, Reinhardt UE. Health care spending and use of information technology in OECD countries. *Health Aff (Millwood)* 2006; 25:819-31.
34. Freedman VA, Martin LG, Schoeni RF. Recent trends in disability and functioning among older adults in the United States: a systematic review. *JAMA* 2002; 288:3137-46. [Erratum, *JAMA* 2003;289: 3242.]

Copyright © 2006 Massachusetts Medical Society.